Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma

A case report and literature review describes a 26-year-old male patient with relapsed/refractory classical Hodgkin lymphoma (cHL) who achieved complete metabolic remission after treatment with the Ven-Chi-Dec regimen. The patient had previously undergone autologous stem cell transplantation (ASCT) but experienced disease progression. The Ven-Chi-Dec regimen combines venetoclax, a BCL-2 inhibitor, with chidamide, a histone deacetylase inhibitor, and decitabine, a hypomethylating agent. This triple therapy was administered for six cycles, resulting in a complete metabolic response without significant adverse effects.

Classical Hodgkin lymphoma is typically treated with chemotherapy and radiation, but relapsed/refractory cases after ASCT pose a therapeutic challenge. Novel agents such as brentuximab vedotin and anti-PD-1/PD-L1 monoclonal antibodies have improved outcomes, but resistance remains an issue. The Ven-Chi-Dec regimen targets multiple pathways, including apoptosis and epigenetic modulation, offering a potential new option for these patients.

This single case report provides preliminary evidence that the Ven-Chi-Dec regimen may be effective and well-tolerated in heavily pretreated cHL. However, the findings are limited by the lack of a control group and the small sample size. Further studies are needed to validate these results and determine the regimen's role in the treatment landscape.

Clinicians should interpret this data with caution, as causality cannot be inferred from a single case. The regimen's efficacy and safety require confirmation in larger, controlled trials before it can be recommended for routine clinical use.